Pulmonary Arterial Hypertension Market Forecast Reveals Positive Growth Trajectory
The global pulmonary arterial hypertension (PAH) market is projected to witness substantial growth over the coming years, with its size estimated to grow from US$ 8.7 billion in 2026 to US$ 14.3 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2026 to 2033. Pulmonary arterial hypertension is a life-threatening condition characterized by elevated blood pressure in the arteries of the lungs, leading to right heart failure. The market expansion is primarily driven by increased disease awareness, better diagnostic capabilities, and advancements in therapeutic treatments.